Elizabeth Masson-Hurlburt
Corporate Officer/Principal presso CORMEDIX INC.
Patrimonio netto: 192 483 $ in data 31/03/2024
Profilo
Elizabeth Masson-Hurlburt is currently the Chief Clinical Strategy & Operations Officer at CorMedix, Inc. Prior to her current position, she worked as the Vice President-Clinical Operations at Gemphire Therapeutics, Inc. from 2016 to 2018.
Ms. Masson-Hurlburt completed her undergraduate degree at Bay Path College.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
CORMEDIX INC.
0.08% | 12/01/2024 | 45 397 ( 0.08% ) | 192 483 $ | 31/03/2024 |
Posizioni attive di Elizabeth Masson-Hurlburt
| Società | Posizione | Inizio |
|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | - |
Precedenti posizioni note di Elizabeth Masson-Hurlburt
| Società | Posizione | Fine |
|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/03/2018 |
Formazione di Elizabeth Masson-Hurlburt
| Bay Path College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
- Borsa valori
- Insiders
- Elizabeth Masson-Hurlburt
